Stockreport

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF In the global Phase 3 innovaTV 301 clinical trial TIVDAK demonstrated superior overall survival compared to chemotherapy TIVDAK is approved for the treatment of recur [Read more]